We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
GlaxoSmithKline (GSK) and Valeant Pharmaceuticals International have filed an NDA for their epilepsy treatment retigabine with the FDA and a marketing authorization application with the European Medicines Agency.